STRO Sutro Biopharma Inc
918
$4.14
$0.06
(1.47%)
| Watchers | 918 |
| 52-Wk Low | $2.01 |
| 52-Wk High | $6.13 |
| Market Cap | $338.63M |
| Volume | 528,017.00 |
| 52-Wk High | $6.13 |
| 52-Wk Low | $2.01 |
Q1 2024 EPS Estimates for Sutro Biopharma, Inc. (NASDAQ:STRO) Boosted by WedbushZolmax • about 2 months ago
Sutro Biopharma, Inc. (NASDAQ:STRO - Free Report) - Research analysts at Wedbush lifted their Q1 2024 earnings per share estimates for shares of Sutro Biopharma in a report issued on Tuesday...
Share to Feed
SOUTH SAN FRANCISCO, Calif., April 02, 2024 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and...
This is a signal that STRO's price could be shifting from an uptrend to a downtrend. Traders may consider selling the stock or exploring put options...
Ipsen secures exclusive global rights for development and commercialization of STRO-003, an antibody-drug conjugate, completing the final stages of pre-clinical developmentSTRO-003 targets ROR1, a...
Sutro Biopharma shares are trading lower by 4.3% during Tuesday's session. The company announced the pricing of an underwritten offering.
read more...
Investors considering a purchase of Sutro Biopharma Inc (STRO) stock, but tentative about paying the going market price of 5.28/share, might benefit from considering selling puts among the...
Shares of Sutro Biopharma (NASDAQ:STRO) have been up over 50% in the past few days on the strength of an earnings beat. The recent acquisition of I...
Oppenheimer reaffirmed their outperform rating on shares of Sutro Biopharma (NASDAQ:STRO - Free Report) in a research note released on Wednesday morning, Benzinga reports. The brokerage currently has...
JMP Securities reissued their market outperform rating on shares of Sutro Biopharma (NASDAQ:STRO - Free Report) in a research report report published on Tuesday morning, Benzinga reports. JMP...
Sutro Biopharma, Inc. (NASDAQ:STRO - Free Report) - Stock analysts at Wedbush decreased their Q1 2024 earnings estimates for shares of Sutro Biopharma in a research report issued to clients and...